MEASURES TO AVOID RISK FROM VALPROATE IN PREGNANCY

摘要

All women of childbearing age prescribed the drug valproate — whioh has been linked to foetal abnormalities — must, in future, take part in a pregnancy prevention programme, according to tighter European drug safety recommendations. The women should be assessed for their pregnancy risk when the drug is prescribed and should routinely be offered a pregnancy test before starting treatment, according to the new recommended guidelines from the European Medicines Agency's Pharmacovigilance Risk Assessment Committee.